Table 1.
Baseline characteristics of included studies.
| Study | Sample size (T/C) | Male (T/C) | Mean age (T/C) | Cardiac function (T/C) | Interventions in both Yiqi Fumai injection and control group | Dose of Yiqi Fumai injection | Treatment period (weeks) | Outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NYHA II | NYHA III | NYHA IV | ||||||||
| Aunt and Nurbia [15] | 60/60 | — | 55.4 (total) | — | — | — | Furosemide, metoprolol | 5.2 g | 2 | a, b, f |
| Diao [16] | 43/43 | 22/21 | 60.3/60.5 | — | — | — | Spironolactone, digoxin | — | 4 | b |
| Dong and Liu [17] | 60/60 | 38/35 | 56.4/56.1 | — | — | — | Enalapril, metoprolol | 5.2 g | 2 | a, b, e |
| Feng [18] | 27/24 | — | 56.0∼86.0 | 12/10 | 12/12 | 3/2 | Spironolactone, metoprolol | 5.2 g | — | b, d |
| Li [19] | 30/30 | 14/17 | 67.5/64.7 | 16/18 | 14/12 | — | Furosemide, metoprolol | 1.3 g | 2 | b |
| Li et al. [20] | 30/30 | 15/15 | 71.1/70.9 | — | — | — | Ramipril, furosemide | 5.2 g | 1.5 | e, f |
| Li [21] | 30/30 | — | 64.3 (total) | — | — | — | Furosemide, captopril | 2.6 g | 4 | b, f, g |
| Li et al. [22] | 59/59 | 35/34 | 68.5/68.3 | — | — | — | Atorvastatin | 5.2 g | 2 | b, e, h |
| Liu [23] | 45/45 | 24/25 | 56.7/55.2 | / | 19/18 | 26/27 | Dobutamine hydrochloride | 5.2 g | 2 | b, e, d, h |
| Lv [24] | 43/40 | 30/28 | 62.7/61.5 | 17/16 | 14/13 | 12/11 | Furosemide, metoprolol | 2.6 g | 2 | h |
| Mao and Song [25] | 30/30 | 17/18 | 58.5/58.6 | — | — | — | Spironolactone, metoprolol | 2.6 g | 2 | b, e |
| Ren [26] | 44/44 | — | 55.0 (total) | — | — | — | Trimetazidine | 5.2 g | 2 | b, e, h |
| Sun [27] | 30/30 | 11/10 | 76.0/74.0 | 6/5 | 15/17 | 9/8 | Enalapril, metoprolol | 3.9 g | 2 | a, b, e, f, c, g |
| Sun [28] | 60/60 | 43/44 | 58.4/58.2 | 16/17 | 26/27 | 18/16 | Captopril, metoprolol | 5.2 g | 2 | b, e, h |
| Wang and He [29] | 35/29 | 19/16 | 54.9/52.5 | 9/7 | 20/18 | 6/4 | Furosemide, digoxin | 3.9 g | 2 | b, c, d, h |
| Wang [30] | 50/50 | 32/30 | 70.0/69.5 | — | — | — | Aspirin, spironolactone | 5.2 g | 2 | b, e, h |
| Wang et al. [31] | 33/32 | 19/18 | 64.3/63.8 | — | — | — | Milrinone | 5.2 g | 1 | a, b, e, c |
| Wang [32] | 49/49 | 32/33 | 76.0/79.0 | — | — | — | Metoprololsuccinate | 5.2 g | 2 | b |
| Wang and Niu [33] | 35/35 | 21/22 | 58.0/59.0 | 10/10 | 18/19 | 7/6 | Isosorbide dinitrate | 3.9 g | 2 | b, c, h |
| Wu [34] | 32/30 | 19/17 | 60.3/62.4 | — | — | — | Enalapril | 2.1 g | 2 | b, c |
| Xi [35] | 79/79 | 39/36 | 56.0/56.0 | — | — | — | Amiodarone, furosemide | 2.6 g | 2 | a |
| Xue et al. [13] | 44/43 | 28/25 | 55.3/55.5 | 7/6 | 28/28 | 9/9 | Captopril, metoprolol | 2.6 g | 2 | a, b |
| Yang and Liu [36] | 60/60 | — | 72.2/73.1 | 6/8 | 54/52 | — | Enalapril, metoprolol | 5.8 g | 2 | b, e |
| Yang [37] | 150/150 | 89/87 | 57.2/56.4 | 29/28 | 96/97 | 25/25 | Captopril, digoxin | 5.2 g | 2 | b, e, f, h |
| Yang et al. [38] | 30/30 | 22/23 | 70.7/70.8 | 8/5 | 18/18 | 4/7 | Enalapril, metoprolol | 5.2 g | 2 | b, e |
| Yang [39] | 30/30 | 16/15 | 69.0/67.8 | 6/6 | 16/18 | 8/7 | Furosemide, metoprolol | 2.6 g | 2 | a |
| Yu and Wang [40] | 30/30 | 15/16 | 66.0/65.0 | 6/6 | 21/20 | 3/4 | Furosemide, spironolactone | 3.9 g | 2 | b, h |
| Yu et al. [11] | 45/45 | 25/23 | 51.5/52.0 | — | — | — | Spironolactone, metoprolol | 2.6 g | 2 | a, b |
| Zhai and Hui [12] | 30/30 | — | 63.0 (total) | 20 | 36 | 4 | Ramipril, furosemide | 5.2 g | 2 | a, b, e, h |
| Zhang [41] | 30/30 | — | 70.0 (total) | 26 | 20 | 14 | Enalapril, metoprolol | 5.2 g | 2 | a, b, e, f, h |
| Zhang [10] | 40/40 | 23/24 | 56.3/55.9 | — | — | — | Furosemide, captopril | 3.9 g | 2 | a, b, e |
| Zhu [42] | 100/100 | 66/66 | 63.7/63.2 | — | — | — | Atorvastatin | 5.2 g | 2 | b, d, h |
| Zhu and Han [43] | 50/50 | 31/28 | 66.2/69.0 | — | — | — | Aspirin, spironolactone | 5.2 g | 2 | a, b, c, d, g |
Notes. Both groups received the same basic treatment; “—” = not reported; T = trial group; C = control group; NYHA = New York Heart Association. Outcomes: a = response rate; b = left ventricular ejection fraction; c = cardiac output; d = left ventricular end-systolic diameter; e = N-terminal pro-brain natriuretic peptide; f = 6-minute walk test; g = quality of life; h = adverse reaction.